Fortunately, depending on the better understanding of the mechanism of some endotypes of myositis-related ILD (e.g., anti-synthetase syndrome and anti-MDA5 positive myositis-related ILD), novel immunologic agents have shown some potential to be used for this purpose (20). This evidence concerns the gene IFIH1 and interstitial lung disease.